A
Ayman El-Kattan
Researcher at Pfizer
Publications - 69
Citations - 4364
Ayman El-Kattan is an academic researcher from Pfizer. The author has contributed to research in topics: Pharmacokinetics & Bioavailability. The author has an hindex of 34, co-authored 69 publications receiving 3825 citations. Previous affiliations of Ayman El-Kattan include University of South Carolina.
Papers
More filters
Journal ArticleDOI
The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems.
TL;DR: The in vitro permeation experiments with hairless mouse skin revealed that the terpene enhancers varied in their ability to enhance the flux of HC, and a linear relationship was established between the log P of terpenes and the cumulative amount of HC in the receptor after 24 h.
Journal ArticleDOI
Enhancement of transdermal drug delivery: chemical and physical approaches.
TL;DR: The enhancing activities and mechanisms of action of some of the more extensively studied chemical penetration enhancers (oxazolidinones, propylene glycol, and epidermal enzymes) are outlined and novel physical strategies, such as the use of microneedles or electroporation are discussed.
Journal ArticleDOI
Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Manthena V.S. Varma,Catherine M. Ambler,Mohammad Ullah,Charles J. Rotter,Hao Sun,John Litchfield,Katherine S. Fenner,Ayman El-Kattan +7 more
TL;DR: It may be qualitatively generalized that targeting intestinal transporters are relevant for drugs with high solubility and/or low passive permeability i.e. a class of compounds identified as Class III and Class IV according to the Biopharmaceutic classification systems.
Journal ArticleDOI
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
Allen J. Duplantier,Stacey L. Becker,Michael John Bohanon,Kris A. Borzilleri,Boris A. Chrunyk,James T. Downs,Lain-Yen Hu,Ayman El-Kattan,Larry C. James,Shenping Liu,Jiemin Lu,Noha Maklad,Mahmoud N. Mansour,Scot Richard Mente,Mary Piotrowski,Subas M. Sakya,Sheehan Susan M,Stefanus J. Steyn,Christine A. Strick,Victoria A. Williams,Lei Zhang +20 more
TL;DR: Subsequent evaluation against the rat DAAO enzyme revealed a divergent SAR versus the human enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.
Journal ArticleDOI
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Jeffrey A. Pfefferkorn,Angel Guzman-Perez,John Litchfield,Robert J. Aiello,Judith L. Treadway,John C. Pettersen,Martha L. Minich,Kevin J. Filipski,Christopher S. Jones,Meihua Tu,Gary Erik Aspnes,Hud Lawrence Risley,Jianwei Bian,Benjamin D. Stevens,Patricia Bourassa,Theresa D’Aquila,Levenia Baker,Nicole Barucci,Alan Robertson,Francis Bourbonais,David R. Derksen,Margit MacDougall,Over Cabrera,Jing Chen,Amanda L. Lapworth,James A. Landro,William J. Zavadoski,Karen Atkinson,Nahor Haddish-Berhane,Beijing Tan,Lili Yao,Rachel E. Kosa,Manthena V.S. Varma,Bo Feng,David B. Duignan,Ayman El-Kattan,Sharad B. Murdande,Shenping Liu,Mark Ammirati,John D. Knafels,Paul DaSilva-Jardine,Laurel Sweet,Spiros Liras,Timothy P. Rolph +43 more
TL;DR: 19 is identified as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species, leading to its selection as a clinical development candidate for treating type 2 diabetes.